Targeted Therapy for Melanomas Without BRAF V600 Mutations

被引：0
作者：
Christian Menzer
Jessica C. Hassel
机构：
[1] University Hospital Heidelberg,Section of DermatoOncology, Department of Dermatology and National Center for Tumor Diseases (NCT)
来源：
Current Treatment Options in Oncology | 2022年 / 23卷
关键词：
Melanoma; MAPK pathway; BRAF; MEK; Targeted therapy; BRAF mutation; V600; Non-V600; Trametinib; Binimetinib; Cobimetinib; C-kit; NRAS; Imatinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Modern therapy of advanced melanoma offers effective targeted therapeutic options in the form of BRAF plus MEK inhibition for patients with BRAF V600 mutations. For patients lacking these mutations, checkpoint inhibition remains the only first-line choice for treatment of metastatic disease. However, approximately half of patients do not respond to immunotherapy, requiring effective options for a second-line treatment. Advances in genetic profiling have found other possible target molecules, especially a wide array of rare non-V600 BRAF mutations which may respond to available targeted therapy.
引用
收藏
页码：831 / 842
页数：11
相关论文
共 483 条
  • [1] Curtin JA(2005)Distinct sets of genetic alterations in melanoma N Engl J Med 353 2135-2147
  • [2] Fridlyand J(2015)Genomic classification of cutaneous melanoma Cell 161 1681-1696
  • [3] Kageshita T(2018)Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 19 603-615
  • [4] Patel HN(2015)Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Lancet 386 444-451
  • [5] Busam KJ(2012)Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma Clin Cancer Res 18 3242-3249
  • [6] Kutzner H(2011)Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis Br J Dermatol 164 776-784
  • [7] Cho KH(2013)Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice Br J Cancer 108 2164-2171
  • [8] Aiba S(2014)Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 1867-1876
  • [9] Bröcker EB(2019)BRAF mutation class and clinical outcomes-letter Clin Cancer Res 25 3188-193
  • [10] LeBoit PE(2016)The molecular profile of metastatic melanoma in Australia Pathology 48 188-1246
12345678910